1
|
Ferlenghi F, Castelli R, Scalvini L, Giorgio C, Corrado M, Tognolini M, Mor M, Lodola A, Vacondio F. Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice. J Pharm Biomed Anal 2019; 180:113067. [PMID: 31891876 DOI: 10.1016/j.jpba.2019.113067] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 12/19/2019] [Accepted: 12/20/2019] [Indexed: 12/24/2022]
Abstract
The interest on the role of gut microbiota in the biotransformation of drugs and xenobiotics has grown over the last decades and a deeper understanding of the mutual interactions is expected to help future improvements in the fields of drug development, toxicological risk assessment and precision medicine. In this paper, a microbiome drug metabolism case is presented, involving a lipophilic small molecule, N-(3β-hydroxy-Δ5-cholen-24-oyl)-l-tryptophan, UniPR1331, active as antagonist of the Eph-ephrin system and effective in vivo in a murine orthotopic model of glioblastoma multiforme (GBM). Following the administration of a single 30 mg/kg dose (p.o.) to mice, maximal plasma levels were reached 30 min after dosing and rapidly declined thereafter. To explain the observed in vivo behaviour, in vitro phase I and II metabolism assays were conducted employing mouse and human liver subcellular fractions and profiling main metabolites by means of tandem (HPLC-ESI-MS/MS) and high resolution mass spectrometry (HPLC-ESI-HR-MS). In the presence of in vitro mouse liver fractions, UniPR1331 showed a low phase I metabolic clearance, despite the identification of a 3-oxo and several hydroxylated metabolites. Conversely, after oral administration of UniPR1331 to mice, a novel isobaric metabolite was detected that (i) was subjected, as parent UniPR1331, to enterohepatic circulation (ii) had not been previously identified in vitro in mouse liver microsomes and (iii) was not observed forming after intraperitoneal (i.p.) administration of UniPR1331. An in vitro faecal fermentation assay produced the same chemical entity supporting a major role of gut microbiota in the in vivo clearance of UniPR1331.
Collapse
Affiliation(s)
- Francesca Ferlenghi
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy
| | - Riccardo Castelli
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy
| | - Laura Scalvini
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy
| | - Carmine Giorgio
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy
| | - Miriam Corrado
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy
| | - Massimiliano Tognolini
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy
| | - Marco Mor
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy
| | - Alessio Lodola
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy.
| | - Federica Vacondio
- Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124, Parma, Italy.
| |
Collapse
|
2
|
Bansal S, Lau AJ. Inhibition of Human Sulfotransferase 2A1-Catalyzed Sulfonation of Lithocholic Acid, Glycolithocholic Acid, and Taurolithocholic Acid by Selective Estrogen Receptor Modulators and Various Analogs and Metabolites. J Pharmacol Exp Ther 2019; 369:389-405. [DOI: 10.1124/jpet.119.256255] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Accepted: 03/25/2019] [Indexed: 12/14/2022] Open
|